Abstracts tagged "Cardiovascular disease"

Abstract Number: 1651 • 2012 ACR/ARHP Annual Meeting
Higher Corticosteroid Doses Early in Disease Have A Long-Term Influence On Metabolic Syndrome in Systemic Lupus Erythematosus: Data from an International Inception Cohort
Ben Parker¹, Murray B. Urowitz², Dafna D. Gladman³, Mark Lunt⁴, Ian N. Bruce⁵ and Systemic Lupus International Collaborating Clinic (SLICC)⁶, ¹Arthritis Research UK Epidemiology Unit, University of Manchester, Manchester, United Kingdom, ²Division of Rheumatology, University of Toronto, Toronto Western Hospital, Toronto, ON, Canada, ³Rheumatology, University of Toronto, Toronto Western Hospital, Toronto, ON, Canada, ⁴Arthritis Research UK Epidemiology Unit, The University of Manchester, Manchester, United Kingdom, ⁵Manchester Academic Health Science Centre, Arthritis Research UK Epidemiology Unit and NIHR Manchester Musculoskeletal Biomedical Research Unit, The University of Manchester, Manchester, United Kingdom, ⁶Toronto
Background/Purpose: The Metabolic Syndrome (MetS) is a clustering of metabolic abnormalities associated with an increased risk of developing diabetes and atherosclerosis, and may add to…
Abstract Number: 872 • 2012 ACR/ARHP Annual Meeting
Monocyte Chemoattractant Protein-1 and Eotaxin Are Associated with Parameters of Cardiac Dysfunction in Juvenile Dermatomyositis
Thomas Schwartz¹, Ivar Sjaastad², Berit Flatø³, Maria Vistnes¹, Geir Christensen¹ and Helga Sanner³, ¹Institute for Experimental Medical Research, Institute for Clinical Medicine, University of Oslo, Oslo, Norway, ²Institute for Clinical Medicine, University of Oslo, Institute for Experimental Medical Research, Oslo University Hospital, Oslo, Norway, ³Department of Rheumatology, Oslo University Hospital, Institute for Clinical Medicine, University of Oslo, Oslo, Norway
Background/Purpose : Juvenile dermatomyositis (JDM) is a vasculopathic disease affecting not only skeletal muscle and skin, but other organs as well. Previously we have shown…
Abstract Number: 68 • 2012 ACR/ARHP Annual Meeting
Cardiovascular Comorbidities Antedating the Diagnosis of Rheumatoid Arthritis
Anne M. Kerola¹, Tuomas Kerola², Markku J. Kauppi², Hannu Kautiainen³, Lauri J. Virta⁴, Kari Puolakka⁵ and Tuomo Nieminen⁶, ¹Medical School, University of Helsinki, Helsinki, Finland, ²Department of Internal Medicine, Päijät-Häme Central Hospital, Lahti, Finland, ³Unit of Primary Health Care, Kuopio University Hospital, Kuopio, Finland, ⁴Research Department, the Social Insurance Institution, Turku, Finland, ⁵Department of Medicine, South Karelia Central Hospital, Lappeenranta, Finland, ⁶Division of Cardiology, Helsinki University Central Hospital, Helsinki, Finland
Background/Purpose: Rheumatoid arthritis (RA) is a chronic inflammatory disease associated with increased cardiovascular morbidity. Evidence suggests that RA patients are at an increased risk of…
Abstract Number: 2563 • 2012 ACR/ARHP Annual Meeting
Factors Associated with Major Cardiovascular Events in Patients with Primary Systemic Necrotizing Vasculitides: Results of a Longitudinal Long-Term Follow-up Study
Benjamin Terrier¹, Christian Pagnoux², Gilles Chironi³, Alain Simon³, Luc Mouthon⁴, Loic Guillevin⁵ and French Vasculitis Study Group (FVSG)⁶, ¹Internal Medicine, Cochin University Hospital, Paris, France, ²Rheumatology, Mount Sinai Hospital, Toronto, Canada, Toronto, ON, Canada, ³HEGP, Paris, France, ⁴Internal Medicine, Hopital Cochin, Paris, France, ⁵Internal Medicine, Division of Internal Medicine, Hôpital Cochin, University Paris Descartes, Paris, France, ⁶Paris
Background/Purpose: Primary systemic necrotizing vasculitides (SNV) were shown to be associated with more frequent subclinical atherosclerosis, independently of cardiovascular (CV) risk factors and C-reactive protein…
Abstract Number: 1443 • 2012 ACR/ARHP Annual Meeting
Caspase-1 Modulates Endothelial Dysfunction and Vascular Repair in Murine Lupus
J. Michelle Kahlenberg¹, Wenpu Zhao², Srilakshmi Yalavarthi² and Mariana J. Kaplan³, ¹Internal Medicine, Division of Rheumatology, University of Michigan, Ann Arbor, MI, ²University of Michigan Rheumatology, Ann Arbor, MI, ³Systemic Autoimmunity Branch, National Institutes of Health/NIAMS, Bethesda, MD
Background/Purpose: Premature cardiovascular disease (CVD) represents a significant cause of morbidity and mortality in systemic lupus erythematosus (SLE). We recently proposed that type I interferon…
Abstract Number: 820 • 2012 ACR/ARHP Annual Meeting
In Rheumatoid Arthritis Incident Fractures Are Associated with an Increased Risk of Cardiovascular Events
Orla Ni Mhuircheartaigh¹, Cynthia S. Crowson², Sherine E. Gabriel³, Veronique L. Roger⁴, L. Joseph Melton III⁵ and Shreyasee Amin⁶, ¹Rheumatology, Mayo Clinic, Rochester, MN, ²Department of Health Sciences Research, Mayo Clinic, Rochester, MN, ³Health Sciences Research & Div of Rheumatology, Mayo Clinic, Rochester, MN, ⁴Health Sciences Research and Cardiology, Mayo Clinic, Rochester, MN, ⁵Department of Hlth Sciences, Mayo Clinic, Rochester, MN, ⁶Health Sciences Research and Rheumatology, Mayo Clinic, Rochester, MN
Background/Purpose: Rheumatoid Arthritis (RA) is associated with an increased risk for both fracture (fx) and cardiovascular disease (CVD) and there is increasing evidence establishing a…
Abstract Number: 69 • 2012 ACR/ARHP Annual Meeting
The Presence of Asymptomatic Carotid Plaques in Patients with Inflammatory Joint Disease Results in Inadequate Treatment to Lipid Targets in Cardiovascular Disease Prevention
Anne G. Semb¹, Silvia Rollefstad², Inge C. Olsen³, Desiree van der Heijde⁴ and Tore K. Kvien⁵, ¹Rheumatology, Diakonhjemmet Hospital, Oslo, Norway, ²Rhuematology, Diakonhjemmet Hospital, Oslo, Norway, ³Department of Rheumatology, Diakonhjemmet Hospital, Oslo, Norway, ⁴Department of Rheumatology, Leiden University Medical Center, Leiden, Netherlands, ⁵Dept. of Rheumatology, Diakonhjemmet Hospital, Oslo, Norway
Background/Purpose: The prevalence of asymptomatic carotid plaque (a-CP) is high in patients with inflammatory joint disease (IJD). Patients with a-CP should receive intensive lipid lowering…
Abstract Number: 2544 • 2012 ACR/ARHP Annual Meeting
Widening Gap Between Cardiovascular Specific Mortality in Patients with Inflammatory Polyarthritis Compared to the General Population?
Alexander J. Warner¹, Jh Humphreys², Mark Lunt³, Tarnya Marshall⁴, Deborah P. M. Symmons⁵ and Suzanne Verstappen⁶, ¹Manchester Academic Health Sciences Centre, Arthritis Research UK Epidemiology Unit, The University of Manchester, Manchester, United Kingdom, ²Manchester Academic Health Science Centre, Arthritis Research UK Epidemiology Unit,, Manchester, United Kingdom, ³Arthritis Research UK Epidemiology Unit, University of Manchester, Manchester Academic Health Science Centre, Manchester, United Kingdom, ⁴Rheumatology, Norfolk and Norwich University Hospitals Trust, Norwich, United Kingdom, ⁵Manchester Academic Health Science Centre, Arthritis Research UK Epidemiology Unit, The University of Manchester, Manchester, United Kingdom, ⁶Arthritis Research UK Epidemiology Unit,, University of Manchester, Manchester Academic Health Sciences Centre, Manchester, United Kingdom
Background/Purpose: Cardiovascular (CVD) mortality rates are raised in patients with inflammatory polyarthritis (IP) but have been shown to be falling in the general population. This…
Abstract Number: 1425 • 2012 ACR/ARHP Annual Meeting
Circulating Free Protein S Levels May Be Linked to Cardiovascular Events and Venous Thrombosis in SLE
Gregg J. Silverman¹, John Jung², Ehtisham Akhter³, Michelle Petri⁴ and Caroline Grönwall², ¹Medical and Pathology, NYU School of Medicine, New York, NY, ²NYU School of Medicine, New York, NY, ³Div of Rheumatology, Johns Hopkins University School of Medicine, Baltimore, MD, ⁴Johns Hopkins University School of Medicine, Baltimore, MD
Background/Purpose: SLE patients are at risk for diverse organ systems involvement, which increases the challenges for diagnosis and predictions for the development of specific clinical…
Abstract Number: 825 • 2012 ACR/ARHP Annual Meeting
Osteoporosis and Vertebral Fractures Are Important Determinants of Cardiovascular Disease in Rheumatoid Arthritis
Ausaf Mohammad¹, Derek Lohan², Diane Bergin², Sarah Mooney², John Newell³, Martin O'Donnell⁴, Robert J. Coughlan¹ and John J. Carey¹, ¹Rheumatology, Galway University Hospitals, Galway, Ireland, ²Radiology, Galway University Hospitals, Galway, Ireland, ³Clinical Research Facility, National University of Ireland, Galway, Ireland, ⁴Clinical Research Facility, Galway University Hospitals, Galway, Ireland
Background/Purpose: Cardiovascular disease(CVD) represents a major comorbidity and the leading cause of mortality for Rheumatoid arthritis(RA) patients. Unfortunately traditional risk factors for CVD underperform in…
Abstract Number: 2688 • 2012 ACR/ARHP Annual Meeting
The Health Improvement and Prevention Program in Systemic Lupus Erythematosus Demonstrates Improvement in Mental Health and Framingham Risk Score At One Year
Paul R. Fortin¹, Ellie Aghdassi², Anne Cymet³, Stacey Morrison⁴, Willy Wynant⁵, Janet E. Pope⁶, Sara Hewitt⁷, Christian A. Pineau⁸, Carolyn Neville⁹, Paula Harvey¹⁰, Jean-Claude Tardif¹¹, Michal Abrahamowicz¹² and Deborah DaCosta¹³, ¹Medicine, Centre de Recherche du Chu de Québec et Université Laval, Quebec City, QC, Canada, ²University Health Network Research Institute - Western Division, Toronto, ON, Canada, ³Nursing, University Health Network - Western Division, Toronto, ON, Canada, ⁴Div Rheumatology Rm MP-10-304, The Toronto Western Hospital, Toronto, ON, Canada, ⁵Division of Clinical Epidemiology, McGill University Health Centre and McGill University, Montreal, QC, Canada, ⁶Medicine/Rheumatology, St. Joseph Health Care London, University of Western Ontario, London, ON, Canada, ⁷Rheumatology, St. Joseph's Health Care, University of Western Ontario, London, ON, Canada, ⁸Rheumatology, McGill University Health Centre, Montreal, QC, Canada, ⁹Epidemiology, Royal Victoria Hospital, Montreal, QC, Canada, ¹⁰Cardiology, Women's College Hospital, Toronto, ON, Canada, ¹¹Montreal Heart Institute, Universite de Montreal endowed research chair in atherosclerosis, Quebec, QC, Canada, ¹²Clinical Epidemiology, McGill University, Montreal, QC, Canada, ¹³Montreal General Hospital, Montreal, Canada
Background/Purpose: The Health Improvement and Prevention Program (HIPP) is a behavioral intervention aimed at improving health status and coping of persons with lupus while reducing…
Abstract Number: 2423 • 2012 ACR/ARHP Annual Meeting
Perceptions Regarding Cardiovascular Risk Factors and Barriers to Risk Reduction Among African American Women with Lupus
Barron Mia¹, Lynne Nemeth¹, Diane L. Kamen² and Youlanda C. Gibbs¹, ¹College of Nursing, Medical University of South Carolina, Charleston, SC, ²Department of Medicine, Arthritis & Clinical Immunology Program, Oklahoma Medical Research Foundation, Charleston, SC
Background/Purpose: Cardiovascular disease (CVD) is highly prevalent among African American (AA) women diagnosed with systemic lupus erythematosus (SLE). Studies have suggested that CVD risk factors…
Abstract Number: 1429 • 2012 ACR/ARHP Annual Meeting
Women with Systemic Lupus Erythematosus (SLE) May Have Different Predictors of Risk for Progression of Aorta Calcium (AS) Than Women without SLE
Apinya Lertratanakul¹, Peggy W. Wu², Alan Dyer¹, William Pearce¹, George Kondos³, Daniel Edmundowicz⁴, James Carr⁵ and Rosalind Ramsey-Goldman⁶, ¹Northwestern University, Chicago, IL, ²Rheumatology, Northwestern University, Chicago, IL, ³University of Illinois at Chicago, Chicago, IL, ⁴Temple University School of Medicine, Philadelphia, PA, ⁵Northwestern University Feinberg School of Medicine, Chicago, IL, ⁶Medicine/Rheumatology, Northwestern University Feinberg School of Medicine, Chicago, IL
Background/Purpose: Women with SLE have increased rates of subclinical atherosclerosis and cardiovascular (CV) events. We investigated which risk factors may be significant in the rate…
Abstract Number: 827 • 2012 ACR/ARHP Annual Meeting
Sustained Development of Cardiovascular Disease in Rheumatoid Arthritis Despite Cardioprotective Treatment: The 10-Year Prospective Carre-Study
Alper M. van Sijl¹, Inge A.M. van den Oever¹, Mike J.L. Peters², Vokko P. van Halm³, Alexandre E. Voskuyl⁴, Yvo M. Smulders⁵ and Mike T. Nurmohamed¹, ¹Rheumatology, Jan van Breemen Research Institute | Reade, Amsterdam, Netherlands, ²Internal medicine, VU University Medical Center, Amsterdam, Netherlands, ³Cardiology, Academic Medical Centre, Amsterdam, Netherlands, ⁴Rheumatology, VU University Medical Center, Amsterdam, Netherlands, ⁵Internal Medicine, VU University Medical Center, Amsterdam, Netherlands
Background/Purpose: Rheumatoid arthritis (RA) is a chronic inflammatory joint disease which is associated with an increased cardiovascular (CV) risk. It is still unknown to what…
Abstract Number: 2685 • 2012 ACR/ARHP Annual Meeting
Overall and Cause Specific Mortality in Patients with Systemic Lupus Erythematosus. A Meta-Analysis of Observational Studies
Marko Yurkovich¹, Kateryna Vostretsova² and J. Antonio Avina-Zubieta³, ¹Department of Medicine, University of British Columbia, Vancouver, BC, Canada, ²University of British Columbia, Vancouver, BC, Canada, ³Rheumatology, Arthritis Research Centre of Canada/University of British Columbia, Richmond, BC, Canada
Background/Purpose: Systemic lupus erythematosus (SLE), is a chronic autoimmune condition. It has the potential to affect any organ system and can be associated with severe…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].